PHAXIAM’s Audit Committee assists our board of directors in its oversight of our corporate accounting and financial reporting and submits the selection of our statutory auditors, their remuneration and independence for approval. It is composed of Hilde Windels and Philippe Archinard for the Board of Directors and Frédéric Mathat and Thibaut du Fayet who represent PHAXIAM’s management team.
Investors
Welcome to the PHAXIAM Therapeutics investor area
Corporate profile
PHAXIAM is a clinical-stage biopharmaceutical company developing innovative bacteriophage-based therapies to fight severe resistant infections.
INNOVATIVE APPROACH
PHAXIAM leverages an innovative approach based on the use of phages, natural viruses that specifically target and kill bacteria. This targeted mechanism offers an effective solution to combat resistant bacterial infections.
PHAGES PORTFOLIO
PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, responsible for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
STOCK MARKET LISTING
PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
STOCK QUOTE
Latest press releases
DATE
TITLE
PDF
March 14, 2025
PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure
.png)
March 06, 2025
PHAXIAM Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication
March 06, 2025
PHAXIAM Announces Suspension Of Trading
January 31, 2025
PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy
January 30, 2025
PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration
January 13, 2025
PHAXIAM Therapeutics announces its financial calendar for 2025
January 7, 2025
PHAXIAM Therapeutics announces updated real-life clinical data from patients treated under the compassionate status in Europe
Upcoming events
June 24th, 2025
PHAXIAM General Assembly - Lyon
September 24th, 2025
Business and 2025 half-year financial results
Audit Committee
Clinical Strategy Committee
Our clinical strategy committee is responsible for analyzing and reviewing our clinical and regulatory strategy. It meets, at least once a year, and makes recommendations to PHAXIAM’s Board of Directors regarding our clinical and regulatory development strategy.
PHAXIAM’s clinical strategy committee is composed of Philippe Archinard and Robert Sebbag for the Board of Directors and Pascal Birman and Thibaut du Fayet who represent PHAXIAM’s management team.
Remuneration and appointments committee
The Remuneration and Appointments Committee hears the directors’ assessments of PHAXIAM’s performance against defined objectives. It meets at least once a year, without the directors being present, to assess their individual performance and, after conferring with them, makes recommendations to the Board of Directors concerning their remuneration.
It is composed of Philippe Archinard, Leïla Nicolas et Hilde Windels for the Board of Directors, and Frédéric Mathat, Chief Financiel Officer of PHAXIAM.
Bylaws, internal rules and miscellaneous
Press releases
DATE
TITLE
PDF
March 14, 2025
PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure
March 06, 2025
PHAXIAM Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication
March 06, 2025
PHAXIAM Announces Suspension Of Trading
January 31, 2025
PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy
January 30, 2025
PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration
January 13, 2025
PHAXIAM Therapeutics announces its financial calendar for 2025
January 7, 2025
PHAXIAM Therapeutics announces updated real-life clinical data from patients treated under the compassionate status in Europe
Past press releases
2024
PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – December 31, 2024
December 31, 2024
PHAXIAM Therapeutics presents clinical data of the PhagoDAIR pilot study, with results confirming the design of the GLORIA Phase II clinical study
December 30, 2024
PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024
Dec 05, 2024
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
Nov 27, 2024
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
Nov 18, 2024
PHAXIAM Reports Third-Quarter 2024 Financial Information
Nov 13, 2024
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024
Nov 08, 2024
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
Nov 04, 2024
Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024
Oct 10, 2024
PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study
Oct 09, 2024
PHAXIAM Provides Business and Financial Update For the First Half of 2024
Sep 25, 2024
Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024
Jul 03, 2024
Results of the combined general meeting of 28 june 2024
Jun 28, 2024
PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024
Jun 07, 2024
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024
Jun 05, 2024
PHAXIAM provides Business and Financial Update for the First Quarter of 2024
May 15, 2024
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
May 03, 2024
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
Apr 15, 2024
Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
Apr 09, 2024
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
Apr 05, 2024
PHAXIAM Announces 2023 Full-Year Results and Provides Business Update
Mar 20, 2024
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
Mar 11, 2024
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Feb 20, 2024
Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024
Feb 06, 2024
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
Jan 18, 2024
Monthly information related to total number of voting rights and shares composing the share capital - December 31, 2023
Jan 03, 2024
2023
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
06/28/2023 - 22:05
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
06/26/2023 - 22:00
Pherecydes Pharma and Erytech Pharma shareholders approve the merger between the two companies
06/23/2023 - 20:45
Commercial Court rejects Akkadian's request to postpone the merger vote: Pherecydes and Erytech shareholders will be able to vote on the merger on June 23, 2023
06/14/2023 - 20:00
Pherecydes Pharma Has Submitted An Application For The Approval Of A Phase I Clinical Study In Infective Endocarditis Caused By Staphylococcus Aureus
06/08/2023 - 07:30
Pherecydes announces that legal proceedings have been initiated against Erytech by Akkadian to obtain the postponement of the vote on the merger with Pherecydes
06/05/2023 - 08:00
Availability of the Exemption document
05/23/2023 - 22:53
PHERECYDES Strengthens its Corporate Links with ERYTECH to Prepare the Strategic Combination
05/16/2023 - 07:00
Pherecydes Pharma presented its Phagogram 1.5 at the ECCMID Congress
04/17/2023 - 07:00
TP ICAP Midcap initiates coverage of Pherecydes Pharma with a “Buy” recommendation
04/06/2023 - 17:45
Pherecydes Pharma selected for the French Tech Health20 program’s 2023 class
03/27/2023 - 07:00
Pherecydes Pharma announces its participation in several scientific and investor conferences
01/25/2023 - 17:45
Pherecydes Pharma Announces its Financial Agenda for 2023
01/03/2023 - 17:45
2022
Pherecydes Pharma: minutes of the Combined General Meeting of December 15, 2022
12/15/2022 - 18:00
Pherecydes Pharma announces the positive recommendation of the DSMB for the continuation of its phase II clinical study PhagoDAIR in osteoarticular infections caused by Staphylococcus aureus
11/29/2022 - 18:00
Pherecydes Pharma will present its phagogram’s latest progress during an oral session at the Phage Futures US 2022 conference
11/16/2022 - 07:00
Half-year 2022 financial results and update on the development plan
10/27/2022 - 17:45
Pherecydes Pharma announces its participation in a number of major scientific and investor conferences
09/27/2022 - 18:00
Pherecydes Pharma successfully completes €3.1 million capital increase
09/22/2022 - 08:30
Pherecydes Pharma launches a capital increase for c. €3m to continue its clinical development program in phage therapy
09/21/2022 - 17:35
Pherecydes Pharma announces the creation of an international Medical Advisory Board
09/15/2022 - 17:45
Pherecydes Pharma announces a first registration of its phagogram as an in vitro diagnostic test in accordance with EC Directives
09/12/2022 - 17:45
Positive preclinical results for inhaled phage therapy presented to the Reanimation 2022 conference
06/27/2022 - 07:00
Pherecydes Pharma announces the enrollment of the first patient in the phase II study PhagoDAIR in the treatment of osteoarticular infections caused by Staphylococcus aureus
06/15/2022 - 18:00
Pherecydes Pharma organizes a scientific symposium during the 23rd National Days of Infectiology
06/08/2022 - 18:00
Pherecydes Pharma obtains AAC Early Access Program approval from the ANSM for its anti-Staphylococcus aureus phages
05/30/2022 - 18:00
The general assembly of Pherecydes Pharma approves the evolution of its governance towards a company with a Board of Directors
05/23/2022 - 19:00
Pherecydes Pharma announces the first international approval of a compassionate treatment with its phages
04/28/2022 - 18:00
Pherecydes Pharma announces its 2021 annual financial results and confirms its 2022 outlook
04/14/2022 - 07:00
Pherecydes Pharma announces the appointment of Thibaut du Fayet as Chief Operating Officer and member of the Executive Board
04/07/2022 - 18:00
Pherecydes Pharma announces partnership with Navarrabiomed to evaluate its anti-S. aureus phages in a new indication
03/31/2022 - 07:00
Pherecydes Pharma granted a new patent for its anti-Pseudomonas aeruginosa phages in Europe
03/22/2022 - 07:00
Pherecydes Pharma and BIOASTER join forces in the treatment of bacteremia
03/11/2022 - 07:00
Pherecydes Pharma extends its intellectual property in China with a first patent granted for its anti-Pseudomonas aeruginosa phages in this territory
03/08/2022 - 17:45
Pherecydes Pharma announces a change in its governance structure to become a Company with a Board of Directors
02/24/2022 - 07:00
Pherecydes Pharma receives a favorable opinion from the Ethics Committee to initiate the PhagoDAIR study
02/07/2022 - 17:45
Pherecydes Pharma Announces its Financial Agenda for 2022
01/10/2022 - 17:45
The PhagECOLI project undertaken by Pherecydes Pharma and the CEA receives a €2 million grant from Bpifrance
01/03/2022 - 18:00
2021
Pherecydes Pharma obtains ANSM approval for its PhagoDAIR program, the world’s first study in precision phage therapy
12/22/2021 - 07:00
Pherecydes Pharma continues to strengthen its intellectual property with a first patent granted in China, for its anti-Staphylococcus aureus phages
12/16/2021 - 07:00
Pherecydes - First patent granted in Israel for anti-Staphylococcus aureus phages and update on the development schedule
11/29/2021 - 07:00
Pherecydes Pharma announces the appointment of Dr. Pascal Birman as Medical Director
10/20/2021 - 18:00
Pherecydes Pharma publishes its half-year 2021 financial results and assesses its positive development momentum
10/13/2021 - 07:00
Pherecydes Pharma announces its participation in a number of major scientific conferences and investor events in H2 2021
09/08/2021 - 17:45
Pherecydes Pharma will present its work on the provision of bacteriophages for therapeutic use at the France Bioproduction congress
06/16/2021 - 17:45
The results of a preclinical trial demonstrating the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia have been published in the prestigious British Journal of Pharmacology
06/07/2021 - 18:00
Pherecydes Pharma expands its patent portfolio with a new patent granted in Hong Kong
05/11/2021 - 07:00
A new scientific publication highlights the beneficial effect of Pherecydes Pharma phages in treating a case of prosthetic knee infection
05/06/2021 - 07:00
Pherecydes Pharma obtains €2 million in non-dilutive financing from Bpifrance
04/29/2021 - 18:00
Portzamparc initiates the coverage of Pherecydes Pharma
04/28/2021 - 07:00
Pherecydes Pharma announces its 2020 annual financial results and confirms its 2021 outlook
04/15/2021 - 07:00
A preclinical trial demonstrates the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia
04/08/2021 - 18:00
Pherecydes Pharma strengthens its Management Committee: recruitment of Céline Breda as Director of Industrial Operations
03/31/2021 - 18:00
Pherecydes Pharma Announces its Financial Agenda for 2021
03/22/2021 - 18:00
Pherecydes Pharma’s phage production project (PhagoPROD) featured in the European Commission’s CORDIS magazine
03/15/2021 - 18:00
Strengthening of Pherecydes Pharma’s patent portfolio with two new patents granted in the United States
02/16/2021 - 18:00
Resounding success of Pherecydes Pharma’s IPO on the Euronext Growth® market in Paris
02/02/2021 - 20:27
Pherecydes Pharma brings forward the closing of its IPO to February 1, 2021, given its strong success with investors
01/29/2021 - 08:20
Pherecydes Pharma announces its intention to list on the Euronext Growth® market in Paris
01/05/2021 - 07:30
Financial calendar and upcoming events
June 24th, 2025
PHAXIAM General Assembly - Lyon
September 24th, 2025
Business and 2025 half-year financial results
Past webcasts
Universal Registration Document
2020
Financial reports
Financial reports
Quarterly Financial Information
2021
2020
2019
2018
2017
2016
2015
Periodical information
Total Numbers of Voting Rights and Shares
2024
2023
2022
2021
2020
2019
2018
Other documents
Equity offerings
2024
2021
Dépôts SEC
Shareholders Meetings
2024
2023
2022
11/30/2022
11/30/2022
05/04/2022
2021
2020
2019
2018
2017
2016
2015
Stock quote
Historical price
Analyst coverage
Company
Analysts
Latest analyst note
Portzamparc
Mohamed Kaabouni
TP ICAP Midcap
Claire Deray
Please note that any opinions, estimates or forecasts regarding PHAXIAM Thepapeutics performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of PHAXIAM Thepapeuticsa or its management. PHAXIAM Thepapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Investor alerts
Would you like to subscribe to our alerts to receive all our investor information directly in your mailbox? Please enter your email address in the field below and select the type of information you are interested in.
We respect your privacy and will not share your data with third parties. You can unsubscribe at any time from alerts to which you have subscribed.
For more information on our data protection policy, please consult our privacy policy.
INVESTORS CONTACT
To contact our investor relations team
PHAXIAM
Thibaut du Fayet
CEO
+33(0)4 78 74 44 38
investors@phaxiam.com
Investor relations
NewCap
Mathilde Bohin / Dusan Oresansky
+33(0)1 44 71 94 94
phaxiam@newcap.eu
Media relations
NewCap
Arthur Rouillé
+33(0)1 44 71 94 94
phaxiam@newcap.eu